Compare · GLP-1 agonist
Ecnoglutide vs Orforglipron
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Orforglipron | |
|---|---|---|
| Evidence | 7/10 | 9/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it…
Orforglipron
Orforglipron (brand name Foundayo) belongs to the same drug family as semaglutide and tirzepatide — a group called GLP-1 receptor agonists (drugs that copy a natural gut hormone to curb appetite and steady blood sugar). But it has one big difference: it is a small molecule rather than a peptide (a…